摘要
戊型肝炎病毒(HEV)感染是引起急性病毒性肝炎的最常见病因之一。大多数HEV感染是无症状的,机体能够自发清除病毒。孕妇、老年人、免疫功能低下人群、慢性肝病患者以及与HEV感染动物密切接触的人员是HEV感染的高风险人群。重组戊型肝炎疫苗HEV 239是目前唯一获批的戊型肝炎疫苗,具有短期和长期的保护效力,该疫苗安全性高,不良反应少,高风险人群应优先接种。免疫功能低下者感染HEV可发生慢性感染。利巴韦林和干扰素是目前治疗HEV感染最常用的抗病毒药物。然而,对于利巴韦林或干扰素治疗有禁忌证或治疗无应答的患者,尚需开发安全有效的新型抗病毒药物。
Hepatitis E virus(HEV)infection is one of the most common causes of acute viral hepatitis.Most patients with HEV infection are asymptomatic and the virus can be spontaneously eliminated.Pregnant women,the elderly,immunocompromised populations,patients with chronic liver disease,and individuals in close contact with HEV-infected animals are at a high risk for HEV infection.The recombinant hepatitis E vaccine HEV 239 is the only approved hepatitis E vaccine,with both short-and long-term protective efficacy.This vaccine has a favorable safety profile with few adverse events,and the high-risk populations should be given the priority to receive such vaccination.Immunocompromised individuals may develop chronic HEV infection.Ribavirin and interferon are currently the most commonly used antiviral drugs for the treatment of HEV infection;however,it still needs to develop safe and effective novel antiviral drugs for patients with contraindications to ribavirin or interferon or those who have no response to such therapy.
作者
朱月萍
朱传武
ZHU Yueping;ZHU Chuanwu(Department of Infectious Diseases,The Fifth People’s Hospital of Suzhou,Suzhou Clinical Medical Center for Infectious Diseases,Suzhou,Jiangsu 215131,China)
出处
《临床肝胆病杂志》
CAS
北大核心
2023年第11期2524-2529,共6页
Journal of Clinical Hepatology
基金
苏州市科学技术局基金项目(SKY2021059)
苏州市姑苏卫生人才计划项目(GSWS2020091)。
关键词
戊型肝炎
高风险人群
病毒性肝炎疫苗
治疗学
Hepatitis E
High-Risk Population
Viral Hepatitis Vaccines
Therapeutics
